Ibuprofen , ≥98%(GC) , 15687-27-1

Synonym(s):
α-Methyl-4-(isobutyl)phenylacetic acid;(±)-2-(4-Isobutylphenyl)propanoic acid;[(±)-2-(4-Isobutylphenyl)-propionic Acid;IB;IBU

CAS NO.：15687-27-1

Empirical Formula: C13H18O2

Molecular Weight: 206.28

MDL number: MFCD00010393

EINECS: 239-784-6

PRODUCT Properties

• Melting point: 77-78 °C
• alpha: [α]D20 -1～+1°(c=1,C2H5OH)
• Boiling point: 157 °C (4 mmHg)
• Density: 1.0364 (rough estimate)
• refractive index: 1.5500 (estimate)
• Flash point: 9℃
• storage temp.: 2-8°C
• solubility: Practically insoluble in water, freely soluble in acetone, in methanol and in methylene chloride. It dissolves in dilute solutions of alkali hydroxides and carbonates.
• pka: pKa 4.45± 0.04(H2O,t = 25±0.5,I=0.15(KCl))(Approximate)
• form: Crystalline Powder
• color: white to off-white
• Water Solubility: insoluble
• Merck: 14,4881
• BCS Class: 2
• Stability: Stable. Combustible. Incompatible with strong oxidizing agents.
• InChIKey: HEFNNWSXXWATRW-UHFFFAOYSA-N
• LogP: 3.970
• CAS DataBase Reference: 15687-27-1(CAS DataBase Reference)
• NIST Chemistry Reference: Ibuprofen(15687-27-1)
• EPA Substance Registry System: Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (15687-27-1)

Description and Uses

Ibuprofen is a white, crystalline anti-infl ammatory drug used in numerous medications. It is the active ingredient marketed under various trade names including Advil, Motrin, and Nurofen. Ibuprofen is a nonsteroidal anti-infl ammatory drug (NSAID) used as a pain reliever (analgesic), fever reducer (antipyretic), and inflammation reducer. Infl ammation is a general physiological response to tissue damage characterized by swelling, pain, and heat.
Ibuprofen works by inhibiting the enzyme cyclooxygenase (COX), which in turn interferes with the synthesis of prostaglandins. COX exists as several coenzyme forms that are similar in structure: COX-1, COX-2, COX-3; ibuprofen is a nonselective inhibitor of both COX-1 and COX-2. COX-1 is continually produced in mammalian cells throughout the body in response to physiological stimuli. It is responsible for the production of prostaglandins, which get their name because it was originally believed they were synthesized in the prostate gland. In fact, prostaglandins are synthesized throughout the body and act like hormones by stimulating action in target cells. Prostaglandins, which are fatty acid compounds consisting of a 20-carbon chain including a 5 carbon ring, are involved in numerous physiological processes including renal function, blood clotting, and stomach mucus production. COX-2 is synthesized only in specifi c parts of the body (kidneys, brain, trachea) as needed and is therefore called an induced enzyme. COX-2 produces prostaglandins in response to tissue damage and infl ammation. Infl ammatory prostaglandins produce swelling, pain, and fever.

A common goal in the development of pain and inflammation medicines has been the creation of compounds that have the ability to treat inflammation, fever, and pain without disrupting other physiological functions. General pain relievers, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. A medication's specificaction toward COX-1 versus COX-2 determines the potential for adverse side effects. Medications with greater specificity toward COX-1 will have greater potential for producing adverse side effects. By deactivating COX-1, nonselective pain relievers increase the chance of undesirable side effects, especially digestive problems such as stomach ulcers and gastrointestinal bleeding. COX-2 inhibitors, such as Vioxx and Celebrex, selectively deactivate COX-2 and do not aff ect COX-1 at prescribed dosages. COX-2 inhibitors are widely prescribed for arthritis and pain relief. In 2004, the Food and Drug Administration (FDA) announced that an increased risk of heart attack and stroke was associated with certain COX-2 inhibitors. This led to warning labels and voluntary removal of products from the market by drug producers; for example, Merck took Vioxx off the market in 2004. Although ibuprofen inhibits both COX-1 and COX-2, it has several times the specificity toward COX-2 compared to aspirin, producing fewer gastrointestinal side effects.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H319-H335
• Precautionary statements: P261-P264-P270-P271-P301+P312-P305+P351+P338
• Hazard Codes: Xn
• Risk Statements: 22-63-51/53-39/23/24/25-23/24/25-11
• Safety Statements: 36-61-36/37-45-16-7
• HS Code: 29163920
• Hazardous Substances Data: 15687-27-1(Hazardous Substances Data)
• Toxicity: LD50 in male mice, rats (mg/kg): 495, 626 i.p.; 1255, 1050 orally (Orzalesi)